We are a vertically integrated medical cannabis company with an operational presence in every part of the medical cannabis supply chain for top-quality cannabis products, including R&D, Growing, Breeding, Nursery, Production, and Distribution. Having built a deep understanding of patients’ needs, Univo is today the largest medical cannabis distributor in Israel, selling its products in over 100 pharmacies nationwide. This allows us to specialize in the research, development, cultivation, and manufacturing of medical cannabis to meet specific demand. Univo produces tons of our own carefully selected cannabis strains every month, used to make dried inflorescences and extracts, while also developing a variety of formulations aimed to address a wide range of medical conditions. Our production plant is equipped with advanced technologies to extract cannabis oil using proprietary Ethanol and CO2 extraction methods. Due to the chemical and physical characteristics of Ethanol and CO2, we can produce various medical whole-plant cannabis-based products that vary in CBD, TCH, and other cannabinoids. The Univo R&D pipeline includes products in a variety of dosage forms, such as powders, tablets, capsules, creams, sprays, and suppositories. Many members of our management and research team are cannabis market experts who hold PhDs in chemistry, analytical chemistry, biomedicine, and pharmaceuticals. They all come together to create innovative and dosage-formed products for the next generation in medical cannabis. Univo (TLV: UNVO), which is a part of the TASE TA-Cannabis Index, is led by CEO Golan Bitton, and Chaired by Chaim Hurvitz who is former Chairman of Galmed Pharmaceuticals, former President of Teva International Group and former President and CEO of Teva Pharmaceuticals Europe. Mr. Hurvitz established CH-health VC firm, where he serves today as CEO.